# Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.

> **NCT02876900** · PHASE3 · COMPLETED · sponsor: **Noven Pharmaceuticals, Inc.** · enrollment: 617 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Low Dose Asenapine maleate transdermal patch
- **DRUG:** High Dose Asenapine maleate transdermal patch
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02876900
- **Lead sponsor:** Noven Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2018-06
- **Final completion:** 2018-06
- **Target enrollment:** 617 (ACTUAL)
- **Last updated:** 2020-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02876900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02876900, "Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02876900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*